Optimizing AML Care Through Academic-Community Collaboration

Author(s):

Margaret T. Kasner, MD,Christian Fidler, MD

Panelists discuss how the decision to refer a patient with secondary AML from community practice to an academic or specialized leukemia program should be based on a combination of disease complexity, treatment requirements, and the community center's capabilities, while emphasizing the importance of ongoing collaboration and education to enhance patient care across all settings.

EP: 1.Implementing Updates to AML Classification Guidelines

EP: 2.Treatment Goals in Secondary AML

EP: 3.The Role of Molecular and Cytogenetic Testing in Secondary AML

EP: 4.Patient-Centered Decision-Making in Secondary AML Treatment

EP: 5.Assessing Transplant Eligibility and Fitness for Intensive Chemotherapy

EP: 6.Evidence-Based Approaches to Intensive Chemotherapy in Secondary AML

EP: 7.Navigating Intensive Chemotherapy in the Community Setting

Now Viewing

EP: 8.Optimizing AML Care Through Academic-Community Collaboration

Video content above is prompted by the following:

At what point should a patient be referred from community practice to an academic or specialized leukemia program?
How can collaboration between academic and community practices be enhanced to improve patient care?
- Please also describe ways providers can stay current with therapeutic updates.